The SL2B aptamer, which can inhibit cancer cell growth by disturbing the vascular endothelial growth factor (VEGF) signaling pathways, was used as an additional modification to the TDN to target colorectal cancer [60]. Here, VEGFA is linked to colorectal cancer.